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Oncolytic virotherapy is a recent addition to cancer treatment. Here, we describe positive treatment outcomes in three
patients using Rigvir virotherapy. One of the patients is diagnosed with melanoma stage IV M1c, one with small cell
lung cancer stage IIIA, and one with histiocytic sarcoma stage IV. The diagnoses of all patients are verified by histol-
ogy or cytology. All patients started Rigvir treatment within a few months after being diagnosed and are currently con-
tinuing Rigvir treatment. The degree of regression of the disease has been determined by computed tomography. Safety
assessment of adverse events graded according to NCI CTCAE did not show any value above grade 1 during Rigvir
treatment. Using current standard treatments, the survival of patients with the present diagnoses is low. In contrast,
the patients described here were diagnosed 3.5, 7.0, and 6.6 years ago, and their condition has improved and been sta-
bile for over 1.5, 6.5, and 4 years, respectively. These observations suggest that virotherapy using Rigvir can success-
fully be used in long-term treatment of patients with melanoma stage IV M1c, small cell lung cancer stage IIIA, and
histiocytic sarcoma stage IV and therefore could be included in prospective clinical studies.
Key words: Histiocytic sarcoma; immunotherapy; melanoma; oncolytic virotherapy; Rigvir; small cell lung cancer;
virotherapy.
Peteris Alberts, International Virotherapy Center, Teatra iela 9, Riga, LV-1050, Latvia. e-mail: peteris@virotherapy.eu
Oncolytic virotherapy is an active immunotherapy in
cancer treatment (1, 2). Rigvir is the first virus that
has been approved as an oncolytic cancer treatment.
It has been registered for melanoma treatment in Lat-
via since 2004 and is included in the national guideli-
nes for melanoma treatment in Latvia where
approximately 75% of melanoma patients are treated
with Rigvir (3–5). Oncolytic virotherapy has recently
been added as a cancer treatment tool in the USA (6,
7). Rigvir has been shown to significantly reduce the
mortality 4.39- to 6.57-fold in melanoma stage IB-IIC
patients in a retrospective study (3, 4). Untoward side
effects and discontinuation of treatment are rare. Rig-
vir has also been used in other cancers, for example,
in gastric and rectal cancer patients, where 5-year sur-
vival was improved (3, 8–10).Received 13 April 2016. Accepted 13 June 2016
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Malignant neoplasms such as melanoma, small
cell lung cancer, and histiocytic sarcoma are all char-
acterized by aggressive progression (11–15). The inci-
dence of melanoma has been increasing in the last
decades, and it is a major health concern. Despite
research and progress in melanoma therapy, mortal-
ity rates still remain high and melanoma is one of the
most common cancers in the Western world. Small
cell lung cancer is considered to be the most
aggressive lung cancer subtype of neuroendocrine
origin. Small cell lung cancer response to chemother-
apy and radiation therapy is high; however, recur-
rence is common and long-term survival does not
exceed 5% (16–18). Histiocytic sarcoma is a rare
hematopoietic disease characterized by malignant
proliferation of cells that resemble mature hepato-
cytes according to their phenotypic, morphological,





Fig. 1. Malignant epithelioid and nevoid melanoma cells. Hematoxylin and eosin stain, magnification (A) 9200, and (B)
9400. Arrow indicates melanoma cells. Scale bar is 100 lm (A and B). (C) S-100 antigen-positive cells. (D) Human mela-
noma black 45 (HMB45) antigen-positive cells. (E) Ki-67 antigen-positive cells. (F) Intratumoral lymphoid infiltrate with
strong CD3 membrane staining. (G) Intratumoral lymphoid infiltrate with strong CD8 membrane staining. Scale bar is
50 lm (C–G).
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limited number of histiocytic sarcoma cases have
been described (less than 100) and often has poor
response to therapy, the disease lacks an accepted
standard treatment (11, 14, 21). The aim of this study
was to describe long-term virotherapy with Rigvir of
a melanoma stage IV M1c patient, a small cell lung
stage IIIA cancer patient, and a patient with histio-
cytic sarcoma stage IV.
MATERIALS AND METHODS
The patients were diagnosed at their respective hospital and
subsequently approached the International Virotherapy
Center. The study has been approved by the local ethics
committee. Written consent has been obtained from the




Fig. 2. Liver CT of the melanoma patient. Contrast-enhanced CT late phase (contrast) shows no visible change in multiple




Fig. 3. Inguinal lymph node CT of the melanoma patient. Abdominal contrast-enhanced CT late phase (contrast) shows
an enlarged inguinal lymph node (encircled) on the right side that is reduced in size by half between August 22, 2013, and
December 1, 2014, and that subsequently has stabilized in size. (A) August 22, 2013, (B) December 1, 2014, (C) May 25,
2015, (D) April 14, 2016.
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Rigvir was obtained from the marketing authorization
holder SIA Latima, Kudras iela 7-8, LV-2114 Olaine,
Latvia.
Rigvir characteristics
Rigvir is a 2 mL frozen solution of an adapted and
selected ECHO-7 virus strain; Picornaviridae family,
Enterovirus genus, Enteric Cytopathic Human Orphan
(ECHO) type 7, group IV, positive-sense single-stranded
RNA virus produced under GMP. The titer is
≥106 TCID50/mL in sodium chloride for injection and is
administered intramuscularly regionally. While Rigvir
therapy can be individualized, physicians that have been
certified to use Rigvir by the International Virotherapy
Center and the Latvian Virotherapy Association are pro-
vided with guidelines on the use of Rigvir that they may
consult to make practical and informed decisions about
specific details of treatment (22).
Safety
In the previous clinical studies, a few side effects were
reported, for example, subfebrile temperature (37.5 °C for
a couple of days), pain in the tumor area, sleepiness, and
diarrhea. In this study, serum clinical chemistry parame-
ters were recorded and graded according to NCI CTCAE
(23).
RESULTS
Case 1: Melanoma IV M1c
A woman born in 1972 diagnosed with malignant
melanoma in the lumbar paraspinal region had the
tumor surgically removed in December 2012; lymph
nodes were left untouched. Histological examina-
tion of the surgical material confirmed the diagnosis
of stage IV M1c melanoma cutis dorsi, Clark V,
Breslow 8–9 mm, pT4bNxM1c, S-100 antigen posi-
tive, human melanoma black 45 (HMB45) antigen
positive, Ki-67 index 10–15%, intratumoral lym-
phoid infiltrate with strong CD3 and CD8 mem-
brane staining, with liver and inguinal lymph node
metastasis (Fig. 1).
Postsurgery in January 2013, the patient received
one palliative chemotherapy course of Lomustine
(200 mg per os) and ondansetron. From week 5,
the patient had fever for 2 weeks where antipyretic
therapy was ineffective, accompanied by weakness,
nausea, vertigo, lack of appetite, impairment of
coordination, hallucinations, and inguinal lymph
node swelling. The chemotherapy was discontin-
ued.
Rigvir therapy was started in February 2013
with daily administrations for 3 days. After
4 weeks, another three daily administrations were
made. Subsequently, administration was regular
A B
Fig. 4. Cytology of biopsy samples of the small cell lung cancer patient. Lymph node small cell cancer cells (purple) and
erythrocytes (blue-green). Light microscopy. Giemsa stain. Scale bar is 100 lm.
Fig. 5. Thoracic lymph node diameter change and therapy
dates of the small cell lung cancer patient. The diameter
of an enlarged lymph node that decreased in size with
time and stabilized during Rigvir treatment (▲) is shown.
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every week. After 24 months, the administration
interval was reduced to once every 2 weeks. Rig-
vir treatment is being continued. The patient has
received no other concomitant treatment. The
number and size of liver lesions show no visible
change (Fig. 2). Moreover, comparison of the
size of an inguinal lymph node shows a reduc-
tion in size ca. twofold, followed by stabilization
(Fig. 3).
When tested starting about 6 months after sur-
gery, circulating lactate dehydrogenase (LDH)
levels are within the normal reference range of the
laboratory and the S-100 antigen levels are below
the reference threshold.
Lymphocyte subpopulations were measured in
blood samples taken in April 2016. The CD3+ (ab-
solute count), activated T-lymphocytes CD3+HLA-
DR+ (absolute and relative count), CD8+ (absolute
count), and HLA-DR+ (absolute count) were below
the reference range. CD38+ (relative levels) and the
ratio of T helpers CD4+/T suppressors CD8+ were
above the reference range. Serum clinical chemistry
parameter values above grade 1 according to NCI
CTCAE (23) were not observed.
Thus, the patient0s condition has improved and
has been stable since December 2014.
Case 2: Small cell lung cancer stage IIIA
A man born in 1934, long-term and still a smo-
ker, with no comorbidity, had shortness of
breath, dyspnea, and cough and was diagnosed
with right upper lobe small cell lung cancer
(pT2N2M0) in May 2009. Metastases were found
in the thoracic mediastinal lymph nodes. Fiber
bronchoscopy showed enlarged lymph nodes in
the right lung. Cytological examination of biopsy
samples of lymph nodes showed poorly differenti-
ated small cell lung cancer (Fig. 4); the patient
was diagnosed with small cell lung cancer by two
cytologists.
The patient has been treated with Rigvir since
June 2009, and the treatment is continuing (Fig. 5).
During the first month, Larifan was also prescribed
weekly; the patient has not received any other con-
comitant treatment.
Lymphocyte subpopulations were measured
in blood samples taken in June 2009 and
June 2016. In comparison, the levels of natural
killer cells (CD16+ and CD56+), CD4+, and
the ratio of T helpers CD4+/T suppressors CD8+
are normalized. The levels of CD3+, CD8+,
CD19+, and CD45+ were all within reference
range.
Comparison of CT scans shows that the diameter
of enlarged lung lymph nodes decreased in size and
subsequently normalized (Fig. 6).
Serum clinical chemistry parameter values above
grade 1 according to NCI CTCAE (23) were not
observed.
Thus, the patient0s condition has improved and
has been stable since October 2009.
A CB
D E F
Fig. 6. CT of the small cell lung cancer patient. Contrast-enhanced CT late phase (contrast) shows an enlarged lymph
node (encircled) on the right side that decreased in size with time and stabilized. (A) April 9, 2009, (B) October 8, 2009,
(C) April 20, 2010, (D) July 29, 2013, (E) August 25, 2014, (F) April 23, 2015.
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Case 3: Histiocytic sarcoma IV
A man born in 1970 had pain in the right side of
the abdomen, fever, and lost about 10 kg of body
weight in a short period of time. Histology of
biopsy samples from lymph nodes of the left side of
the neck in October 2009 shows characteristic histi-
ocytic sarcoma (Fig. 7). The biopsy samples were
positive for the specific markers CD68, CD163, and
lysozyme (14, 24) as well as for CD8, CD43, S-100,
and leukocyte common antigen (LCA). Ki-67 index
was 80%; the cells were negative for cytokeratin
AE1/AE3 (Ck AE1/AE3), epithelial membrane
antigen (EMA), CD4, CD56, and HMB45, as
determined by immunohistochemistry.
The patient has not had surgery. In October
2009, he was prescribed symptomatic treatment.
Rigvir has been administered on average every
3 weeks for 6 years, except for two intermissions,
and the treatment is continuing.
In the autumn of 2011, the patient was referred
by the Virotherapy Center to the Oncological Cen-
ter for a medical examination. He was then treated
with radiotherapy applied to the lymph nodes of
the neck, the para-aortic and iliac lymph nodes,
and of the mediastinum, with 6 courses of doxoru-
bicin and cyclophosphamide. At the Oncological
Center, he has received Helixor P for some time
besides Rigvir (cf. (25)).
Lymphocyte subpopulations were measured in
blood samples taken in November 2009 and June
2016. In comparison, the levels of CD3+ (absolute
count), CD4+ (absolute and relative count), and the
ratio of T helpers CD4+/T suppressors CD8+ are




Fig. 7. Lymph node biopsy samples of the histiocytic sarcoma patient. (A) Hematoxylin–eosin stain, magnification 940;
(B) hematoxylin–eosin stain, magnification 9200; (C) hematoxylin–eosin stain, magnification 9400; (D) LCA-positive
tumor cells, immunohistochemistry, magnification 9200; (E) CD20-positive tumor cells, immunohistochemistry, magnifica-
tion 9200; (F) S-100-positive tumor cells, immunohistochemistry, magnification 9200; (G) CD68-positive tumor cells,
immunohistochemistry, magnification 9200; (H) CD163-positive tumor cells, immunohistochemistry, magnification 9200;
(I) lysozyme-positive tumor cells, immunohistochemistry, magnification 9200. Scale bar is 50 lm.
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natural killer cells (CD16+ and CD56+), CD8+,
CD19+, and CD45+ were all within reference
range.
The size of abdominal, neck, and thorax lymph
nodes has been reduced (Figs 8 and 9).
Serum clinical chemistry parameter values above
grade 1 according to NCI CTCAE (23) were not
observed during Rigvir treatment. However, during




Fig. 8. CT of the histiocytic sarcoma patient. Contrast-enhanced CT late phase (contrast) of abdominal lymph nodes that













































Fig. 9. Lymph node size and therapy dates of the histiocytic sarcoma patient. Abdominal, neck, and thorax lymph node
(L.n.) diameters peaked and then decreased in size with time and stabilized. Dates of Rigvir administration (+), chemo-
therapy ( ), and radiotherapy (▲) treatment.
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Thus, the patient0s condition has improved and
has been stable since April 2012.
DISCUSSION
The three patients described here have been diag-
nosed with melanoma stage IV M1c, small cell lung
cancer stage IIIA, and histiocytic sarcoma stage IV.
They have been long-term treated with Rigvir
virotherapy starting from 1 to 2 months after diag-
nosis during 3.5, 7.0, and 6.6 years, respectively.
The expected 3-year survival of stage IV mela-
noma patients treated according to current standard
treatments is approximately 15% (26). The predicted
3.5-year survival for melanoma stage IV M1c group
patients is approximately 10% (12, 13); however, the
latter estimate does not include subgrouping by nor-
mal and elevated serum LDH levels at the time of
diagnosis. In melanoma stage IV patients with nor-
mal LDH levels independent of M1 subgroup, the
3.5-year survival is approximately 30% (12, 13). In a
recent study, the 3-year survival in stage IVb and IVc
melanoma patients was approximately 19–23% (6).
While the expected survival time for half of the stage
IV M1c melanoma patients is approximately
6 months (13), the present patient was diagnosed
more than 42 months ago.
The 5-year survival for small cell lung cancer
stage III with current standard treatment has been
calculated to be 8.2% (15, 27). While the expected
survival time for half of these patients is approxi-
mately 12 months (27), the present patient was
diagnosed more than 85 months ago.
Histiocytic sarcoma is a rare disease with only few
cases described in the literature, and consequently,
there is no accepted standard treatment (14, 21). The
relative 5-year survival for the age 25–64 group to
77% (28). A recent retrospective study calculated the
overall 5-year survival to 45% (N = 9) (14). Histio-
cytic sarcoma is often characterized by aggressive
progression with little response to therapy (11, 14,
21). The present result might suggest that in this par-
ticular patient Rigvir pretreatment slowed down the
disease progression and sensitized the tumor tissue to
chemo- and radiotherapy.
The authors are indebted to Andra Tilgase for critical
review of the manuscript.
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